What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Cagrilintide + Semaglutide combination
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing CagriSema inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
CagriSema is a fixed-combination preparation of the long-acting amylin analog Cagrilintide and the GLP-1 receptor agonist Semaglutide, currently in Novo Nordisk's Phase 3 REDEFINE clinical-development program for chronic weight management. The combination represents the next-generation evolution of GLP-1-based weight-management pharmacology by adding the amylin-axis mechanism (acting on the area postrema and calcitonin-receptor family) to the GLP-1 receptor mechanism, producing additive weight-reduction signals that exceed Semaglutide monotherapy in head-to-head dose-equivalent comparisons. The standard ratio is 1:1 by mass of Cagrilintide to Semaglutide, though custom ratios are available for research applications studying ratio-dependent biology. PeptideXpo supplies CagriSema as a pre-blended co-lyophilized product at ≥99.0% HPLC purity for each component, batch-released against a documented ratio rather than just total mass. Co-lyophilization is preferred over solution-phase mixing because amylin-class peptides have surface-mediated aggregation sensitivity in dilute solution. The release packet certifies both component purities individually plus the actual ratio in the released vial (typically within ±5% of nominal). Three fill sizes (5, 10, 20 mg total) cover both research and compounding workflows.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Investigational combination product (Novo Nordisk REDEFINE program); not approved as a finished drug at the time of writing. Component-level analytical data and verified ratio supplied for every batch.
Frequently asked questions
Amylin-class peptides (including Cagrilintide) have a documented sensitivity to surface-mediated aggregation when held in dilute aqueous solution, the same biology that drives native amylin to form fibrils in the pancreas under disease conditions. Co-lyophilizing Cagrilintide with Semaglutide produces a stable solid-state product where the ratio is locked in by the lyophilization step and surface-aggregation issues don't manifest until reconstitution at point of use. Solution-phase mixing of separately-purchased Cagrilintide and Semaglutide vials is operationally possible but produces variable ratios and degraded amylin component over time. The pre-blended product also simplifies the documentation chain: a single COA certifies both components and the verified ratio.
Cagrilintide acts on the amylin and calcitonin receptor family at the area postrema, contributing to satiety signaling and gastric-emptying delay. Semaglutide acts on the GLP-1 receptor in the arcuate nucleus and peripheral tissues, contributing to appetite suppression and insulinotropic effects. The two signaling axes are anatomically and pharmacologically distinct, they converge on common downstream effects (reduced food intake, weight reduction) but through parallel rather than redundant pathways. The clinical-program rationale is that combining the two produces additive weight-reduction beyond what either monotherapy can achieve at maximal tolerable doses, which the Phase 2 REDEFINE-2 data supported.
Related peptides
